Median progression-free of charge survival was 16.0 months in women and 9.0 months in men . Median overall survival was 29.0 months in ladies and 18.0 months in men . There were no significant variations in progression-free survival according to performance status, age, first-collection therapy versus third-line or second-line therapy, smoking background, or type of mutation . In a multivariate analysis , there is a link between poor progression-free survival and male sex and the current presence of the L858R mutation . In the multivariate analysis of general survival, an ECOG overall performance status of 1 1, male sex, the current presence of the L858R mutation, and the analysis of bronchioloalveolar adenocarcinoma had been connected with poor prognosis .To be opened with remarks from Ron Geraty, MD, CEO of Alere. Alere’s robust Apollo fully integrates an array of health management programs about the same IT system. It incorporates personal wellness records, telehealth monitoring and case management alerts and also wellness and high acuity persistent care programs. The Apollo platform uses applied health research and clinical guidelines to create a unique, compelling and personalized user experience that offers an individual watch of a member’s health status across the entire continuum of treatment.